Patrys and Garvan Institute of Medical Research Awarded Grant
Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…
New US patent for Patrys PAT-LM1
Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…
Universal Biosensors receives $7.5M under the R&D Tax Incentive
Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…
Medical Device Industry Sign Historic Agreement to Reduce Health Fund Premiums
The Medical Technology Association of Australia (MTAA) has signed a four-year Agreement with the Federal Government which will deliver certainty and stability to the industry and will help lower Private Health Insurance (PHI) premiums for Australians. The Agreement,…
GKC names John Schellhorn new President and CEO
GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…
LBT Receives $4.2 Million in R&D Incentives
Australian medical technology company LBT Innovations Limited (ASX:LBT) has received an R&D Incentive, net of income tax payable, of $3.98 Million for the financial year ended 30 June 2017. In addition, LBT has also received $0.22 Million for…
Starpharma – DEP® docetaxel positive phase 1 results; phase 2 commences
DEP® docetaxel phase 1 trial successfully completed with phase 2 to commence immediately DEP® docetaxel patients had no reports of neutropenia, a life-threatening toxicity seen in virtually all patients treated with conventional docetaxel formulations (e.g. Taxotere®) Encouraging signs of efficacy observed…
Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden
Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical technology company focussed on the development and commercialisation of innovative cancer-related tests, is pleased to announce the appointment of Axlab A/S as its exclusive distribution partner…
Penthrox is recommended for use in all UK ambulances
Medical Developments International Ltd (ASX: MVP) is delighted to advise the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) has issued its new pain management clinical practice guidelines for UK ambulance services teams. The JRCALC guidelines now recommend the…
U.S. Patent Granted for Cynata Cymerus™ Technology
Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.…
St Vincent’s Hospital Commences Global First APAS® In Situ Automated Evaluation
Australian developed advanced pathology instrument reading and interpreting plates for faster diagnosis of infectious diseases Centre of excellence laboratory to test automation efficiency in a busy real-life setting Adelaide, Australia, 27 September 2017: Australian medical technology…
Hydrix & Panorama
Today it was announced that Panorama Synergy Limited (ASX: PSY) has entered into an agreement to fully acquire Hydrix through an asset purchase agreement. This is an exciting development for both companies with the Merged Group at the…
